The Obesity Crisis and the Coming Revolution in Canadian Healthcare
Picture this: A 67-year-old woman in Ottawa, Bonnie Evoy, battles rapid weight gain through relentless dieting and daily exercise—even when injured. Her doctor prescribes a groundbreaking medication, but she abandons treatment not because it failed, but because she couldn’t afford it. This isn’t a story from a developing nation; it’s Canada in 2025. The arrival of generic GLP-1 drugs like Ozempic could reshape this landscape, but the real question isn’t about cost—it’s about whether our healthcare system has the courage to redefine what it means to treat a chronic illness.
Why Obesity Medications Aren’t Just About Weight Loss
Let’s cut through the noise: Obesity isn’t a failure of willpower. It’s a complex, chronic disease with biological roots that Canada’s policymakers have shamefully underfunded for decades. When experts argue for public coverage of GLP-1s, they’re not advocating for vanity-driven weight loss—they’re demanding recognition of a medical reality. These drugs don’t just shift numbers on a scale; they slash risks of heart disease, diabetes, and even certain cancers. Yet, provinces cling to the archaic notion that obesity is a “lifestyle choice,” while silently paying billions to manage its consequences. The hypocrisy is staggering.
Here’s what few admit aloud: Covering Ozempic only for diabetes patients is a cowardly loophole. It treats the symptom (high blood sugar) while ignoring the underlying disease (obesity). Alberta’s symbolic recognition of obesity as chronic doesn’t matter if they won’t fund treatments. This bureaucratic gamesmanship isn’t saving money—it’s delaying inevitable, costlier interventions like heart surgeries and dialysis.
The Economic Case: Pay Now or Pay Far More Later
In my opinion, the math here is irrefutable. At $1,000 annually per patient, generic semaglutide sounds expensive—until you compare it to the $30,000 a year Canada spends managing severe obesity complications. What many people don’t realize is that every dollar invested in preventive obesity care ripples across the economy: fewer sick days, reduced disability claims, and less strain on emergency rooms. Dr. Freedhoff calls this the “inevitability of coverage,” but I see a deeper truth: resisting this shift isn’t fiscal responsibility—it’s short-term greed masking as prudence.
Consider this paradox: Private insurers already cover GLP-1s for employees, recognizing their ROI. Yet public plans, which serve the most vulnerable, hesitate. Why? The answer lies in stigma. Politicians fear accusations of subsidizing “cosmetic” results, even as they quietly budget for obesity’s downstream costs. It’s a morally bankrupt calculus that prioritizes optics over lives.
Beyond BMI: Rethinking Eligibility Criteria
The obsession with BMI thresholds as gatekeepers for treatment deserves scrutiny. Dr. Sockalingam rightly argues that BMI alone is a blunt instrument—like using a thermometer to diagnose pneumonia. Should we deny medication to someone with a BMI of 32 but pre-diabetic bloodwork? Or wait until their health crumbles to “qualify” for care? The coming generics flood forces a critical question: Will provinces use this price drop to expand access preemptively, or double down on rationing?
A provocative angle: Universal coverage for GLP-1s could inadvertently worsen health inequities. If public plans cover only the bare minimum (e.g., BMI >40 with diabetes), while wealthier Canadians access private clinics for optimized regimens, we’ll create a two-tiered obesity treatment system. This mirrors the IVF debate—life-changing care available only to those who can pay.
The Stigma That Shapes Policy
Let’s address the elephant in the room: Obesity care is underfunded because we blame victims. No one shames a breast cancer patient for needing Herceptin, yet obesity patients are routinely lectured about “personal responsibility.” Dr. Kwon identifies this stigma as a roadblock, but I’d argue it’s the roadblock. Until we confront our puritanical hang-ups about food and weight, policies will remain stuck in a cycle of reactive, crisis-driven care.
This isn’t just about drugs—it’s about cultural reckoning. When provinces refuse to cover obesity medications, they send a message louder than any public health campaign: “Your disease isn’t real.” The result? Patients like Evoy abandon treatment, not from lack of need, but from lack of institutional support.
What the Future Should Hold
As generics arrive, I’m betting this becomes a litmus test for progressive healthcare. Provinces that act boldly—using semaglutide as a springboard to overhaul obesity care—will see dividends in productivity and reduced healthcare burdens. Those that don’t? They’ll keep paying the same old price, plus interest. The pCPA’s stalemate with Novo Nordisk proves negotiations are messy, but the endgame is clear: Accessibility must trump perfectionism.
Final thought: Maybe the real breakthrough isn’t the drug itself, but the crisis it exposes. Generic Ozempic could be the catalyst that finally forces Canada to confront its outdated views on obesity. Or we’ll squander this moment, leaving patients to navigate a maze of exclusions and denials. Either way, history won’t judge gently those who chose inaction over empathy.
